Gefitinib
- PDF / 169,167 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 17 Downloads / 179 Views
1 S
Development of resistance: case report In a retrospective study involving 36 patients with non-small cell lung cancer (NCSLC) who received first line treatment with gefitinib between January 2012 and December 2018, one patient [age and sex not stated] was described, who developed drug resistance during the treatment with gefitinib. The patient with NCSLC, started receiving first line treatment with oral gefitinib 250 mg/day; however, the patient developed an uncommon EGFR mutation (G719X mutation in exon 18) during the treatment resulting in disease progression [duration of treatment to reaction onset not stated]. Therefore, the patient was started on hypo-fractionated, high dose radiation therapy, and the gefitinib therapy was continued [outcome not stated]. Santarpia M, et al. High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: Real world data. In Vivo 34: 2009-2014, No. 4, Aug 803501800 2020. Available from: URL: http://doi.org/10.21873/invivo.11999
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
